ZIM Laboratories Limited manufactures, markets, and sells formulation drugs and pre formulation ingredients in India and internationally.
Adequate balance sheet with questionable track record.
Share Price & News
How has ZIM Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 541400's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 541400 underperformed the Indian Pharmaceuticals industry which returned 43.7% over the past year.
Return vs Market: 541400 underperformed the Indian Market which returned 1.4% over the past year.
Price Volatility Vs. Market
How volatile is ZIM Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is ZIM Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 541400 (₹91.15) is trading above our estimate of fair value (₹6.59)
Significantly Below Fair Value: 541400 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 541400 is poor value based on its PE Ratio (44.9x) compared to the IN Pharmaceuticals industry average (21.5x).
PE vs Market: 541400 is poor value based on its PE Ratio (44.9x) compared to the Indian market (13x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 541400's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 541400 is good value based on its PB Ratio (1x) compared to the IN Pharmaceuticals industry average (1.9x).
How is ZIM Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ZIM Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine ZIM Laboratories's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- ZIM Laboratories competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has ZIM Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 541400 has high quality earnings.
Growing Profit Margin: 541400's current net profit margins (1.2%) are lower than last year (4.6%).
Past Earnings Growth Analysis
Earnings Trend: 541400 has become profitable over the past 5 years, growing earnings by 24.6% per year.
Accelerating Growth: 541400's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 541400 had negative earnings growth (-78.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (15.9%).
Return on Equity
High ROE: 541400's Return on Equity (2.1%) is considered low.
How is ZIM Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 541400's short term assets (₹1.8B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: 541400's short term assets (₹1.8B) exceed its long term liabilities (₹280.5M).
Debt to Equity History and Analysis
Debt Level: 541400's debt to equity ratio (50.1%) is considered high.
Reducing Debt: 541400's debt to equity ratio has reduced from 98.7% to 50.1% over the past 5 years.
Debt Coverage: 541400's debt is well covered by operating cash flow (28.4%).
Interest Coverage: 541400's interest payments on its debt are not well covered by EBIT (0.6x coverage).
What is ZIM Laboratories's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 541400's dividend (0.55%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.67%).
High Dividend: 541400's dividend (0.55%) is low compared to the top 25% of dividend payers in the Indian market (2.78%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 541400 has been paying a dividend for less than 10 years.
Growing Dividend: 541400 has only been paying a dividend for 2 years, and since then payments have not increased.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (24.6%), 541400's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Anwar Siraj Daud, M.Pharm has been the Managing Director of Zim Laboratories Limited since April 01, 2009. He also serves as Chairman of the Zim Laboratories Limited and has been its Executive Director ...
CEO Compensation Analysis
Compensation vs Market: Anwar's total compensation ($USD0.00) is below average for companies of similar size in the Indian market ($USD49.49K).
Compensation vs Earnings: Insufficient data to compare Anwar's compensation with company performance.
|Executive Chairman & MD||no data||no data||27.43% |
|Director of Administration & Executive Director||22.58yrs||no data||0.021% |
|Director of Business Development & Executive Director||6.75yrs||no data||0.46% |
|Director of Finance & Executive Director||7.83yrs||no data||2.45% |
|Director of Operations & Whole-Time Executive Director||6.75yrs||no data||0.47% |
|Independent Director||10.42yrs||no data||0.0025% |
|Chairman Emeritus||no data||₹600.00k||17.54% |
|Independent Nominee Director||no data||no data||no data|
|Independent Director||7.83yrs||no data||no data|
|Independent Director||12.08yrs||no data||no data|
|Independent Director||2.92yrs||no data||no data|
|Independent Director||2.92yrs||no data||no data|
Experienced Board: 541400's board of directors are considered experienced (7.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
ZIM Laboratories Limited's company bio, employee growth, exchange listings and data sources
- Name: ZIM Laboratories Limited
- Ticker: 541400
- Exchange: BSE
- Founded: 1984
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹1.448b
- Shares outstanding: 16.24m
- Website: https://www.zimlab.in
- ZIM Laboratories Limited
- Sadoday Gyan
- Ground Floor
- 440 013
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|541400||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Jun 2018|
ZIM Laboratories Limited manufactures, markets, and sells formulation drugs and pre formulation ingredients in India and internationally. The company offers technology-based drug delivery solutions and non ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/03 12:59|
|End of Day Share Price||2020/08/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.